Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Histological and immunohistochemical characterization of the porcine ocular surface.

Crespo-Moral M, García-Posadas L, López-García A, Diebold Y.

PLoS One. 2020 Jan 13;15(1):e0227732. doi: 10.1371/journal.pone.0227732. eCollection 2020.

2.

Functional ibuprofen-loaded cationic nanoemulsion: Development and optimization for dry eye disease treatment.

Jurišić Dukovski B, Juretić M, Bračko D, Randjelović D, Savić S, Crespo Moral M, Diebold Y, Filipović-Grčić J, Pepić I, Lovrić J.

Int J Pharm. 2020 Feb 25;576:118979. doi: 10.1016/j.ijpharm.2019.118979. Epub 2019 Dec 21.

PMID:
31870964
3.

Reliability and reproducibility of a rodent model of choroidal neovascularization based on the subretinal injection of polyethylene glycol.

Fernandez-Bueno I, Alonso-Alonso ML, Garcia-Gutierrez MT, Diebold Y.

Mol Vis. 2019 Mar 18;25:194-203. eCollection 2019.

4.

Topical Application of TGF-β-Activating Peptide, KRFK, Prevents Inflammatory Manifestations in the TSP-1-Deficient Mouse Model of Chronic Ocular Inflammation.

Soriano-Romaní L, Contreras-Ruiz L, López-García A, Diebold Y, Masli S.

Int J Mol Sci. 2018 Dec 20;20(1). pii: E9. doi: 10.3390/ijms20010009.

5.

Context-Dependent Regulation of Conjunctival Goblet Cell Function by Allergic Mediators.

García-Posadas L, Hodges RR, Diebold Y, Dartt DA.

Sci Rep. 2018 Aug 15;8(1):12162. doi: 10.1038/s41598-018-30002-x.

6.

Sorbitan ester nanoparticles (SENS) as a novel topical ocular drug delivery system: Design, optimization, and in vitro/ex vivo evaluation.

Alvarez-Trabado J, López-García A, Martín-Pastor M, Diebold Y, Sanchez A.

Int J Pharm. 2018 Jul 30;546(1-2):20-30. doi: 10.1016/j.ijpharm.2018.05.015. Epub 2018 May 16.

PMID:
29753904
7.

Ocular findings in Zucker Diabetic Fatty rats emphasize the key role of neuroglia degeneration in diabetic retinopathy pathophysiology.

Fernandez-Bueno I, Diebold Y.

Neural Regen Res. 2018 Feb;13(2):239-240. doi: 10.4103/1673-5374.226391. No abstract available.

8.

Cross-linked hyaluronan films loaded with acetazolamide-cyclodextrin-triethanolamine complexes for glaucoma treatment.

Calles JA, Mora MJ, Onnainty R, Tartara LI, Granero GE, Longhi MR, Diebold Y, Vallés EM, Palma SD.

Ther Deliv. 2018 Feb 1;9(3):205-220. doi: 10.4155/tde-2017-0087.

PMID:
29424292
9.

Improved in vitro corneal delivery of a thrombospondin-1-derived peptide using a liposomal formulation.

Soriano-Romaní L, Álvarez-Trabado J, López-García A, Molina-Martínez I, Herrero-Vanrell R, Diebold Y.

Exp Eye Res. 2018 Feb;167:118-121. doi: 10.1016/j.exer.2017.12.002. Epub 2017 Dec 12.

PMID:
29246497
10.

Histologic Characterization of Retina Neuroglia Modifications in Diabetic Zucker Diabetic Fatty Rats.

Fernandez-Bueno I, Jones R, Soriano-Romaní L, López-García A, Galvin O, Cheetham S, Diebold Y.

Invest Ophthalmol Vis Sci. 2017 Sep 1;58(11):4925-4933. doi: 10.1167/iovs.17-21742.

PMID:
28973338
11.

Designing lipid nanoparticles for topical ocular drug delivery.

Alvarez-Trabado J, Diebold Y, Sanchez A.

Int J Pharm. 2017 Oct 30;532(1):204-217. doi: 10.1016/j.ijpharm.2017.09.017. Epub 2017 Sep 8. Review.

PMID:
28893582
12.

An engineered human conjunctival-like tissue to study ocular surface inflammatory diseases.

García-Posadas L, Soriano-Romaní L, López-García A, Diebold Y.

PLoS One. 2017 Mar 1;12(3):e0171099. doi: 10.1371/journal.pone.0171099. eCollection 2017.

13.

Novel anti-inflammatory liposomal formulation for the pre-ocular tear film: In vitro and ex vivo functionality studies in corneal epithelial cells.

Soriano-Romaní L, Vicario-de-la-Torre M, Crespo-Moral M, López-García A, Herrero-Vanrell R, Molina-Martínez IT, Diebold Y.

Exp Eye Res. 2017 Jan;154:79-87. doi: 10.1016/j.exer.2016.11.010. Epub 2016 Nov 11.

PMID:
27840060
14.

Preliminary characterization of dexamethasone-loaded cross-linked hyaluronic acid films for topical ocular therapy.

Calles JA, López-García A, Vallés EM, Palma SD, Diebold Y.

Int J Pharm. 2016 Jul 25;509(1-2):237-243. doi: 10.1016/j.ijpharm.2016.05.054. Epub 2016 May 27.

PMID:
27242313
15.

Inflammatory Cytokine-Mediated Regulation of Thrombospondin-1 and CD36 in Conjunctival Cells.

Soriano-Romaní L, Contreras-Ruiz L, García-Posadas L, López-García A, Masli S, Diebold Y.

J Ocul Pharmacol Ther. 2015 Sep;31(7):419-28. doi: 10.1089/jop.2015.0029. Epub 2015 Jul 8.

16.

Interaction of IFN-γ with cholinergic agonists to modulate rat and human goblet cell function.

García-Posadas L, Hodges RR, Li D, Shatos MA, Storr-Paulsen T, Diebold Y, Dartt DA.

Mucosal Immunol. 2016 Jan;9(1):206-17. doi: 10.1038/mi.2015.53. Epub 2015 Jul 1.

17.

Conjunctival Goblet Cell Function: Effect of Contact Lens Wear and Cytokines.

García-Posadas L, Contreras-Ruiz L, Soriano-Romaní L, Dartt DA, Diebold Y.

Eye Contact Lens. 2016 Mar;42(2):83-90. doi: 10.1097/ICL.0000000000000158. Review.

18.

Thrombospondin-1 induces differential response in human corneal and conjunctival epithelial cells lines under in vitro inflammatory and apoptotic conditions.

Soriano-Romaní L, García-Posadas L, López-García A, Paraoan L, Diebold Y.

Exp Eye Res. 2015 May;134:1-14. doi: 10.1016/j.exer.2015.03.004. Epub 2015 Mar 6.

PMID:
25753839
19.

Nanoparticles based on naturally-occurring biopolymers as versatile delivery platforms for delicate bioactive molecules: an application for ocular gene silencing.

Parraga JE, Zorzi GK, Diebold Y, Seijo B, Sanchez A.

Int J Pharm. 2014 Dec 30;477(1-2):12-20. doi: 10.1016/j.ijpharm.2014.09.049. Epub 2014 Sep 30.

PMID:
25275936
20.

Purinergic receptors in ocular inflammation.

Guzman-Aranguez A, Gasull X, Diebold Y, Pintor J.

Mediators Inflamm. 2014;2014:320906. doi: 10.1155/2014/320906. Epub 2014 Jul 14. Review.

21.

IL-6 as a corneal wound healing mediator in an in vitro scratch assay.

Arranz-Valsero I, Soriano-Romaní L, García-Posadas L, López-García A, Diebold Y.

Exp Eye Res. 2014 Aug;125:183-92. doi: 10.1016/j.exer.2014.06.012. Epub 2014 Jun 24.

PMID:
24971496
22.

CD44 and RHAMM hyaluronan receptors in human ocular surface inflammation.

García-Posadas L, Contreras-Ruiz L, Arranz-Valsero I, López-García A, Calonge M, Diebold Y.

Graefes Arch Clin Exp Ophthalmol. 2014 Aug;252(8):1289-95. doi: 10.1007/s00417-014-2686-3. Epub 2014 Jun 12.

PMID:
24916930
23.

Trefoil factor family peptide 3 (TFF3) is upregulated under experimental conditions similar to dry eye disease and supports corneal wound healing effects in vitro.

Schulze U, Hampel U, Sel S, Contreras-Ruiz L, Schicht M, Dieckow J, Diebold Y, Paulsen F.

Invest Ophthalmol Vis Sci. 2014 May 8;55(5):3037-42. doi: 10.1167/iovs.13-13423.

PMID:
24713479
24.

A new human primary epithelial cell culture model to study conjunctival inflammation.

García-Posadas L, Arranz-Valsero I, López-García A, Soriano-Romaní L, Diebold Y.

Invest Ophthalmol Vis Sci. 2013 Oct 29;54(10):7143-52. doi: 10.1167/iovs.13-12866.

PMID:
24106119
25.

Novel bioadhesive hyaluronan-itaconic acid crosslinked films for ocular therapy.

Calles JA, Tártara LI, Lopez-García A, Diebold Y, Palma SD, Vallés EM.

Int J Pharm. 2013 Oct 15;455(1-2):48-56. doi: 10.1016/j.ijpharm.2013.07.063. Epub 2013 Aug 1.

PMID:
23911915
26.

Involvement of corneal epithelial cells in the Th17 response in an in vitro bacterial inflammation model.

Arranz-Valsero I, Schulze U, Contreras-Ruiz L, García-Posadas L, López-García A, Paulsen F, Diebold Y.

Mol Vis. 2013;19:85-99. Epub 2013 Jan 17.

27.

A nanomedicine to treat ocular surface inflammation: performance on an experimental dry eye murine model.

Contreras-Ruiz L, Zorzi GK, Hileeto D, López-García A, Calonge M, Seijo B, Sánchez A, Diebold Y.

Gene Ther. 2013 May;20(5):467-77. doi: 10.1038/gt.2012.56. Epub 2012 Jul 19.

PMID:
22809996
28.

Structural and functional alteration of corneal epithelial barrier under inflammatory conditions.

Contreras-Ruiz L, Schulze U, García-Posadas L, Arranz-Valsero I, López-García A, Paulsen F, Diebold Y.

Curr Eye Res. 2012 Nov;37(11):971-81. doi: 10.3109/02713683.2012.700756. Epub 2012 Jun 27.

PMID:
22738643
29.

Hyaluronan receptors in the human ocular surface: a descriptive and comparative study of RHAMM and CD44 in tissues, cell lines and freshly collected samples.

García-Posadas L, Contreras-Ruiz L, López-García A, Villarón Álvarez S, Maldonado MJ, Diebold Y.

Histochem Cell Biol. 2012 Feb;137(2):165-76. doi: 10.1007/s00418-011-0878-z. Epub 2011 Nov 18.

PMID:
22095138
30.

Expression of MUC5AC in ocular surface epithelial cells using cationized gelatin nanoparticles.

Konat Zorzi G, Contreras-Ruiz L, Párraga JE, López-García A, Romero Bello R, Diebold Y, Seijo B, Sánchez A.

Mol Pharm. 2011 Oct 3;8(5):1783-8. doi: 10.1021/mp200155t. Epub 2011 Aug 2.

PMID:
21770384
31.

Intracellular trafficking of hyaluronic acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells.

Contreras-Ruiz L, de la Fuente M, Párraga JE, López-García A, Fernández I, Seijo B, Sánchez A, Calonge M, Diebold Y.

Mol Vis. 2011 Jan 27;17:279-90.

32.

Applications of nanoparticles in ophthalmology.

Diebold Y, Calonge M.

Prog Retin Eye Res. 2010 Nov;29(6):596-609. doi: 10.1016/j.preteyeres.2010.08.002. Epub 2010 Sep 6. Review.

PMID:
20826225
33.

Dry eye disease as an inflammatory disorder.

Calonge M, Enríquez-de-Salamanca A, Diebold Y, González-García MJ, Reinoso R, Herreras JM, Corell A.

Ocul Immunol Inflamm. 2010 Aug;18(4):244-53. doi: 10.3109/09273941003721926. Review.

PMID:
20482396
34.

Ocular tolerance to a topical formulation of hyaluronic acid and chitosan-based nanoparticles.

Contreras-Ruiz L, de la Fuente M, García-Vázquez C, Sáez V, Seijo B, Alonso MJ, Calonge M, Diebold Y.

Cornea. 2010 May;29(5):550-8. doi: 10.1097/ICO.0b013e3181bd9eee.

PMID:
20335805
35.

Characterization and short-term culture of cells recovered from human conjunctival epithelium by minimally invasive means.

Martínez-Osorio H, Calonge M, Corell A, Reinoso R, López A, Fernández I, San José EG, Diebold Y.

Mol Vis. 2009 Oct 27;15:2185-95.

36.
37.

Branched-chain fatty acids, increased in tears of blepharitis patients, are not toxic for conjunctival cells.

Joffre C, Souchier M, Leclere L, Buteau B, Grégoire S, Lizard G, Montange T, Acar N, Bron A, Creuzot-Garcher C, Diebold Y, Bretillon L.

Br J Ophthalmol. 2009 Oct;93(10):1391-5. doi: 10.1136/bjo.2008.156356. Epub 2009 Jun 10.

38.

Genetically engineered elastin-like polymer as a substratum to culture cells from the ocular surface.

Martínez-Osorio H, Juárez-Campo M, Diebold Y, Girotti A, Alonso M, Arias FJ, Rodríguez-Cabello JC, García-Vázquez C, Calonge M.

Curr Eye Res. 2009 Jan;34(1):48-56. doi: 10.1080/02713680802542053.

PMID:
19172470
39.

Somatostatin actions via somatostatin receptors on the ocular surface are modulated by inflammatory processes.

Minsel I, Mentlein R, Sel S, Diebold Y, Bräuer L, Mühlbauer E, Paulsen FP.

Endocrinology. 2009 May;150(5):2254-63. doi: 10.1210/en.2008-0577. Epub 2008 Dec 23.

PMID:
19106227
40.

Cytokine responses by conjunctival epithelial cells: an in vitro model of ocular inflammation.

Enríquez-de-Salamanca A, Calder V, Gao J, Galatowicz G, García-Vázquez C, Fernández I, Stern ME, Diebold Y, Calonge M.

Cytokine. 2008 Oct;44(1):160-7. doi: 10.1016/j.cyto.2008.07.007. Epub 2008 Aug 28.

PMID:
18760623
41.

Variation in the expression of inflammatory markers and neuroreceptors in human conjunctival epithelial cells.

Calonge M, De Salamanca AE, Siemasko KF, Diebold Y, Gao J, Juárez-Campo M, Stern ME.

Ocul Surf. 2005 Oct;3(4 Suppl):S145-8.

PMID:
17216105
42.

Lymphocytic infiltration and goblet cell marker alteration in the conjunctiva of the MRL/MpJ-Fas(lpr) mouse model of Sjögren's syndrome.

Diebold Y, Chen LL, Tepavcevic V, Ferdman D, Hodges RR, Dartt DA.

Exp Eye Res. 2007 Mar;84(3):500-12. Epub 2007 Jan 17.

PMID:
17208228
43.

Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP).

Diebold Y, Jarrín M, Sáez V, Carvalho EL, Orea M, Calonge M, Seijo B, Alonso MJ.

Biomaterials. 2007 Mar;28(8):1553-64. Epub 2006 Dec 13.

PMID:
17169422
44.

Altered expression of neurotransmitter receptors and neuromediators in vernal keratoconjunctivitis.

Motterle L, Diebold Y, Enríquez de Salamanca A, Saez V, Garcia-Vazquez C, Stern ME, Calonge M, Leonardi A.

Arch Ophthalmol. 2006 Apr;124(4):462-8.

PMID:
16606870
45.

Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance.

Enríquez de Salamanca A, Diebold Y, Calonge M, García-Vazquez C, Callejo S, Vila A, Alonso MJ.

Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1416-25.

PMID:
16565375
46.

Alpha2-adrenergic receptors are present in normal human conjunctiva.

Diebold Y, Enríquez de Salamanca A, Calonge M, Sáez V, Callejo S, Stern ME.

Curr Eye Res. 2005 Dec;30(12):1121-9.

PMID:
16354626
47.

Expression of muscarinic and adrenergic receptors in normal human conjunctival epithelium.

Enríquez de Salamanca A, Siemasko KF, Diebold Y, Calonge M, Gao J, Juárez-Campo M, Stern ME.

Invest Ophthalmol Vis Sci. 2005 Feb;46(2):504-13.

PMID:
15671275
48.

Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity.

de Campos AM, Diebold Y, Carvalho EL, Sánchez A, Alonso MJ.

Pharm Res. 2004 May;21(5):803-10. Erratum in: Pharm Res. 2005 Jun;22(6):1007.

PMID:
15180338
49.

Impression cytology of the ocular surface: a review.

Calonge M, Diebold Y, Sáez V, Enríquez de Salamanca A, García-Vázquez C, Corrales RM, Herreras JM.

Exp Eye Res. 2004 Mar;78(3):457-72. Review.

PMID:
15106925
50.

Characterization of a spontaneously immortalized cell line (IOBA-NHC) from normal human conjunctiva.

Diebold Y, Calonge M, Enríquez de Salamanca A, Callejo S, Corrales RM, Sáez V, Siemasko KF, Stern ME.

Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4263-74.

PMID:
14507870

Supplemental Content

Loading ...
Support Center